food; average intake 103 ± 4 mg/kg/day). Half of the rats in each group was studied after 12 weeks of treatment, at the age of 34 weeks; the other half at the age of 54 weeks.At the end of treatment, indexes of systemic and regional hemodynamics were measured in conscious instrumented rats. Radiomicrospheres were used for flow measurements. Results: E decreased mean arterial pressure after 12 and 32 weeks of treatment; it did not affect left ventricular (LV) mass; and E decreased LV hydroxyproline concentration (an estimate of collagen) after 32 weeks of therapy. E did not affect coronary blood flow and resistance under basal conditions, but decreased minimal coronary vascular resistance (MCVR) and increased coronary flow reserve, measured after dipyridamole infusion.
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The
Effects of Aspirin on Blood Pressure in Untreated Hypertensive Patients Are Dependent on the Time of Drug Administration
Ramon C. Hermida, Diana E. Ayala, Carlos Calvo, Maria J. Dominguez, Manuel Covelo, Jose R. Fernandez, Artemio Mojon, Jose E. Lopez, University of Vigo, Vigo, Spain, Hospital Clinico Universitario, Santiago, Spain
Background: An administration time-dependent effect of low-dose aspirin (ASA) on blood pressure (BP) has been previously documented in normotensive volunteers, patients with mild hypertension, and pregnant women at high risk for preeclampsia [Hermida et al. Hypertension. 2003; 41:651-656 and 2003; 41:1259 -1267 . We have extended these results by investigating the influence of ASA on BP in previously untreated hypertensive patients who received ASA at different times of the day according to their rest-activity cycle. Methods: We studied 264 untreated patients with mild hypertension (101 men), 43.6±12.6 (mean±SD) years of age, randomly divided in 3 groups: non-pharmacological hygienic-dietary recommendations (HDR); the same HDR and ASA (100 mg/day) on awakening; or HDR and ASA (100 mg/day) before bedtime. BP was measured every 20 min from 07:00 to 23:00 hours and every 30 min at night for 48 consecutive hours before and after 3 months of intervention. The circadian pattern of BP in each group was established by population multiple-component analysis. Results: After 3 months of non-pharmacological intervention, there was a small and nonsignificant reduction of BP (0.4 and 0.5 mm Hg for systolic and diastolic BP; P>0.584). BP was slightly elevated after ASA on awakening, mainly during nocturnal resting hours (increase of 2.7 and 1.5 mm Hg in the 24-hour mean of systolic and diastolic BP; P<0.020). A highly significant BP reduction was, however, observed in the patients who received ASA before bedtime (decrease of 7.1 and 4.6 mm Hg in systolic and diastolic BP, respectively; P<0.001).
Conclusion: This trial corroborates the highly significant administration-time dependent effect of low-dose ASA on BP in untreated patients with mild hypertension. Results indicate that the timed administration of low-dose ASA with respect to the rest-activity cycle of each patient could provide a valuable approach not just for the secondary prevention of cardiovascular disease, but also in the added BP control of patients with mild essential hypertension and poor compliance with HDR. , patients with HTN and CAD were randomized to either a verapamil-SR based (Ve) or atenolol based (At) treatment strategy and followed 2.7 years (mean). Trandolapril and HCTZ were available in both strategies to achieve JNC VI BP goals (<140/<90 or <130/<85 in diabetes or renal dysfunction). The primary outcome (PO) was time to first occurrence of death (all-cause), nonfatal MI or nonfatal stroke. This analysis includes 10,617 patients with ischemia at baseline. RESULTS: See table. BP reduction, control and outcomes were similar comparing strategies. At 24 months, presence of angina was also similar and reduced from baseline. Heart rate (HR) and systolic BP-HR product were significantly lower in the At strategy, however episodes of angina / month was significantly lower in the Ve strategy. CONCLUSIONS: Despite decreased indices of cardiac oxygen demand in the At strategy, patients in the Ve strategy had a greater reduction of anginal episodes, suggesting an alternate mechanism of action for reduced anginal symptoms from verapamil-SR . 
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